• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

估算澳大利亚国家眼部健康调查中发现的黑素细胞性脉络膜肿瘤的恶性风险。

Estimating malignancy risk of melanocytic choroidal tumours detected in the Australian National Eye Health Survey.

机构信息

Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia.

Ophthalmology, Department of Surgery, University of Melbourne, Melbourne, Australia.

出版信息

Clin Exp Optom. 2021 Nov;104(8):854-858. doi: 10.1080/08164622.2021.1878862. Epub 2021 Mar 2.

DOI:10.1080/08164622.2021.1878862
PMID:33689655
Abstract

: The malignant potential of choroidal melanocytic tumours detected incidentally in the community is thought to be low, but this has not been assessed using a validated screening tool. An accurate characterisation of the malignant potential of these lesions has implications for resource allocation, service provision, education, and training.: MOLES (Mushroom shape, Orange Pigment, Large size, Enlargement, and Subretinal fluid) categorises tumours as 'common naevus', 'low-risk naevus', 'high-risk naevus', and 'probable melanoma'. The MOLES system recommends that patients with common naevi (score = 0) undergo review by a community optometrist every two years, ideally with sequential colour photography. For the remaining patients (score ≥ 1), specialist imaging and assessment are recommended, with referral triaged as non-urgent for patients with low-risk (score = 1) or high-risk naevi (score = 2) and urgent for patients with probable melanoma (score > 2).: Lesions flagged as choroidal melanocytic tumours on retinal photographs taken during the Australian National Eye Health Survey were retrospectively analysed by an ocular oncologist. Each lesion was assigned a MOLES score and categorised as common, low-risk, high-risk or probable melanoma.: Seventy-seven choroidal naevi were identified. Seventy-five (97%) of the choroidal naevi were categorised as common naevi, with a MOLES score of 0. Two (3%) choroidal naevi had a score of 1 and diagnosed as low-risk naevi due to their size. No naevi had a score of 2 or more.: All choroidal naevi detected in this nationally representative population survey were innocuous. This suggests that the vast majority of choroidal melanocytic tumours that are incidentally detected in Australia can be managed in primary eye care settings without the need for specialist referral. MOLES provides a simple evidence-based method for choroidal naevi assessment in primary care.

摘要

: 社区中偶然发现的脉络膜黑色素瘤的恶性潜能被认为较低,但尚未使用经过验证的筛查工具对此进行评估。准确描述这些病变的恶性潜能对资源分配、服务提供、教育和培训都有影响。: MOLES(蘑菇形状、橙色色素、大尺寸、增大和视网膜下液)将肿瘤分为“常见痣”、“低风险痣”、“高风险痣”和“可能的黑色素瘤”。MOLES 系统建议常见痣(得分为 0)患者每两年由社区验光师进行复查,最好采用连续彩色摄影。对于其余患者(得分≥1),建议进行专科成像和评估,并根据低风险(得分为 1)或高风险痣(得分为 2)患者的情况进行非紧急转诊,对于可能的黑色素瘤(得分>2)患者则进行紧急转诊。: 在澳大利亚国家眼部健康调查期间拍摄的视网膜照片上标记为脉络膜黑色素瘤的病变由眼肿瘤科医生进行回顾性分析。每个病变都被分配了一个 MOLES 评分,并被归类为常见、低风险、高风险或可能的黑色素瘤。: 共发现 77 个脉络膜痣。75 个(97%)脉络膜痣被归类为常见痣,MOLES 评分为 0。2 个(3%)脉络膜痣的评分是 1,由于其大小被诊断为低风险痣。没有痣的评分是 2 或更高。: 在这项具有全国代表性的人群调查中发现的所有脉络膜痣都是良性的。这表明,在澳大利亚偶然发现的绝大多数脉络膜黑色素瘤可以在初级眼科保健环境中进行管理,而无需专科转诊。MOLES 为初级保健中的脉络膜痣评估提供了一种简单的基于证据的方法。

相似文献

1
Estimating malignancy risk of melanocytic choroidal tumours detected in the Australian National Eye Health Survey.估算澳大利亚国家眼部健康调查中发现的黑素细胞性脉络膜肿瘤的恶性风险。
Clin Exp Optom. 2021 Nov;104(8):854-858. doi: 10.1080/08164622.2021.1878862. Epub 2021 Mar 2.
2
Can the MOLES acronym and scoring system improve the management of patients with melanocytic choroidal tumours?MOLES 缩写和评分系统能否改善脉络膜黑素瘤患者的管理?
Eye (Lond). 2023 Apr;37(5):830-836. doi: 10.1038/s41433-022-02143-x. Epub 2022 Jun 28.
3
The MOLES system to guide the management of melanocytic choroidal tumours: can optometrists apply it?MOLES 系统指导黑素细胞性脉络膜肿瘤的管理:视光师可以应用它吗?
Clin Exp Optom. 2023 Apr;106(3):271-275. doi: 10.1080/08164622.2022.2029685. Epub 2022 Feb 13.
4
Real-world experience of implementing the MOLES score in a virtual choroidal naevi clinic at a tertiary referral centre.在一家三级转诊中心的虚拟脉络膜痣诊所实施 MOLES 评分的真实世界经验。
Eye (Lond). 2024 Apr;38(6):1183-1188. doi: 10.1038/s41433-023-02864-7. Epub 2023 Dec 6.
5
'Mind your Moles' study: protocol of a prospective cohort study of melanocytic naevi.“关注你的痣”研究:一项黑素细胞痣前瞻性队列研究的方案
BMJ Open. 2018 Sep 19;8(9):e025857. doi: 10.1136/bmjopen-2018-025857.
6
The MOLES System for Planning Management of Melanocytic Choroidal Tumors: Is It Safe?用于脉络膜黑素细胞瘤规划管理的MOLES系统:它安全吗?
Cancers (Basel). 2020 May 21;12(5):1311. doi: 10.3390/cancers12051311.
7
Ocular pigmented findings in patients with dysplastic naevus syndrome.发育异常痣综合征患者的眼部色素沉着表现。
Melanoma Res. 2004 Feb;14(1):43-7. doi: 10.1097/00008390-200402000-00007.
8
Detecting Progression of Melanocytic Choroidal Tumors by Sequential Imaging: Is Ultrasonography Necessary?通过序列成像检测脉络膜黑素细胞肿瘤的进展:超声检查是否必要?
Cancers (Basel). 2020 Jul 10;12(7):1856. doi: 10.3390/cancers12071856.
9
Is Tumour Thickness Measurement Required for MOLES Scoring of Melanocytic Choroidal Tumours?脉络膜黑素细胞瘤MOLES评分是否需要测量肿瘤厚度?
Ocul Oncol Pathol. 2023 Aug;9(1-2):40-47. doi: 10.1159/000529862. Epub 2023 Apr 10.
10
High naevus count and MC1R red hair alleles contribute synergistically to increased melanoma risk.痣数量多和 MC1R 红发等位基因协同作用增加黑色素瘤风险。
Br J Dermatol. 2019 Nov;181(5):1009-1016. doi: 10.1111/bjd.17833. Epub 2019 Jul 17.

引用本文的文献

1
Survey of Australian primary eyecare management of choroidal nevus patients.澳大利亚脉络膜痣患者初级眼保健管理调查。
Optom Vis Sci. 2025 Jul 1;102(7):452-457. doi: 10.1097/OPX.0000000000002256. Epub 2025 Apr 21.
2
Multimodal imaging risk factors predictive of small choroidal melanocytic lesion growth to melanoma: An educational study and pictorial guide.预测小脉络膜黑素细胞病变发展为黑色素瘤的多模态成像危险因素:一项教育性研究及图片指南
Eye (Lond). 2024 Mar;38(4):798-805. doi: 10.1038/s41433-023-02782-8. Epub 2023 Oct 25.